Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study

Tison, Alice; Quéré, Gilles; Misery, L.; Funck‐Brentano, Elisa; Danlos, François‐Xavier; Routier, Émilie; Robert, Caroline; Loriot, Yohann; Lambotte, Olivier; Bonniaud, B.; Scalbert, C.; Maanaoui, Sarah; Lesimple, Thierry; Martinez, Stéphanie; Marcq, M.; Chouaïd, C.; Dubos, Cathérine; Brunet‐Possenti, F.; Stavris, C.; Chiche, Laurent; Bénéton, N.; Mansard, Sandrine; Guisier, Florian; Doubre, H.; Skowron, F.; Aubin, F.; Zehou, O.; Rogé, C.; Lambert, Mickaël; Pham‐Ledard, Anne; Beylot‐Barry, M.; Veillon, Rémi; Kramkimel, N.; Giacchero, Damien; De Quatrebarbes, Julie; Michel, Catherine; Auliac, J.B.; Gonzales, Gilles; Decroisette, C.; Le Garff, G.; Carpiuc, Ioana; Vallerand, H.; Nowak, Emmanuel; Cornec, Divi; Kostine, Marie; de Cancérologie Cutanée, Groupe Français de Pneumo‐Cancérologie, and Club Rhumatismes et Inflammations, Groupe

doi:10.1002/art.41068

Public

Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study

Published in Arthritis & Rheumatology • Aug 5, 2019

Authors:

Alice Tison

Gilles Quéré

L. Misery

Abstract

OBJECTIVE: Immune checkpoint inhibitors (ICIs) for cancer therapy frequently induce immune-related adverse effects (IRAEs). Therefore, most patients with preexisting autoimmune diseases have been excluded from clinical trials of ICIs. This study was undertaken to evaluate the safety and efficacy of ...

Subject

Medicine

Internal medicine

Discontinuation

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!